Newsfile Corp
03 May 2026, 16:00 UTC · 21w ago
Verdict
Headline takes no side. We score SES −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 94% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Soleno Therapeutics is alleged to have concealed evidence of safety concerns, specifically excess fluid retention, in Phase 3 clinical trials for DCCR.
More negative than 99% of claims this week
A class action lawsuit has been filed against Soleno Therapeutics and its officers for alleged federal securities law violations.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 90% of claims this week
The lawsuit claims that DCCR has lower commercial viability due to risks of high patient discontinuation and prescriber reluctance.
So whatClaims regarding poor commercial adoption directly challenge the company's long-term revenue projections and valuation.
More negative than 85% of claims this week
Which stocks this story touches
More negative than 94% of ticker scores this week
The company is the subject of a class action lawsuit alleging investor harm.
More negative than 94% of ticker scores this week
The company is the subject of a class action lawsuit alleging investor harm.
More negative than 94% of ticker scores this week
The company is the subject of a class action lawsuit alleging investor harm.
More negative than 94% of ticker scores this week
The company is facing a class action lawsuit alleging the concealment of safety concerns and misrepresented clinical trial data.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
3h ago
−49.3%
Price agrees with the score
$0.5322 vs $1.05 close before publication (May 1) · not market-adjusted
SES chart →
